Graphite Bio is set to merge with LENZ Therapeutics through a reverse merger, via an all-stock transaction. The merged company will continue to operate under the name LENZ Therapeutics and trade on the Nasdaq under the ticker symbol “LENZ”. The merged entity will focus on advancing LENZ’s pipeline candidates intended to address presbyopia, with an estimated US market opportunity exceeding $3bn. The transaction is expected to close in Q1 2024.
OIG: OCR should expand scope of HIPAA audit program
The HHS Office of Inspector General (OIG) has called for the Office for Civil Rights (OCR) to expand its HIPAA audit program and define audit
